Go to AAD Home
Donate For Public and Patients Store Search
Go to AAD Home
Main menu
Membership
Meetings & Education
Practice management
Clinical & quality
Publications & apps
Career development
Advocacy
Back
Account
Pay dues
Member ID
Join the AAD
Member benefits
Find a member
AAD election
AAD governance
Support AAD
AAD Help Center
2025 Annual Meeting
2025 Innovation Academy
Academy meetings archive
Professional education
Claim CME & view transcript
Upcoming events
Residents & medical students
Patient education materials
DataDerm
Coding Resource Center
MIPS & fee schedule
Teledermatology
EHR & health tech
Insurance & drugs
Compliance & practice scope
Managing your practice
Clinical guidelines
Quality measures
DataDerm
Quality & patient safety
Clinical Community
Clinical care resources
Position statements
JAAD
JAAD International
JAAD Case Reports
Dermatology World
DermWorld Insights & Inquiries
Derm Coding Consult
DermWorld Meeting News
Impact Report
Other publications
Academy Apps
Job board
Join or sell a practice
Burnout & wellness
Career launch
Diversity
Awards, grants, and scholarships
Leadership Institute
Volunteer opportunities
Ethics & professionalism
Take action
Advocacy priorities
State advocacy resources
Legislative Conference
Position statements
Promote the specialty
Key Contacts
Patient advocate resources
SkinPAC
Advocacy Update
Welcome!

New treatments provide more options for people with alopecia areata

Journal of the American Academy of Dermatology article highlights new ways to restore hair

ROSEMONT, Ill. (Aug. 15, 2023) — A study published today in a supplement of the Journal of the American Academy of Dermatology titled “Alopecia: A New Frontier” reveals that a new type of medication called JAK inhibitors can effectively treat moderate to severe alopecia areata — a type of hair loss — that has historically been difficult to treat.

“Because alopecia areata is an inflammatory condition, a JAK inhibitor will essentially reduce the inflammation that is fueling the disease and bring your immune system back into balance,” said board-certified dermatologist Sandra Johnson, MD, FAAD, who is an adjunct professor at the University of Arkansas for Medical Sciences. “The development of JAK inhibitors has given us another treatment to improve the lives of patients with alopecia areata.”

The most common sign of alopecia areata is often sudden hair loss, Dr. Johnson said. The patches of hair loss can grow larger, and sometimes become one large bald spot, or spread to your entire head or body.

While anyone can get alopecia areata, the disease is more common in children, those who have a close blood relative who has the disease, and people who have been treated for cancer with a drug called nivolumab, Dr. Johnson said. Having other medical conditions such as asthma, hay fever, eczema, thyroid disease, vitiligo, and Down syndrome also increases a person’s risks for developing alopecia areata.

Courtney Martens first noticed a bald patch about the size of a silver dollar on her scalp when she was 38. She quickly started losing more hair, and eventually lost all hair on her scalp, eyebrows, and eyelashes.

In 2017, Martens learned that she had a condition called alopecia areata, an immune disease that causes the body to attack its own hair follicles, which in turn results in bald spots. Two years later, the Edmond, Okla. mother-of-two heard about a clinical trial at Dr. Johnson’s practice in Fort Smith, Ark., where she received treatment and was able to completely regrow her hair.

“It’s pretty traumatizing,” Martens said. “Most people think it’s just hair, but it was exhausting because it became what everybody talked about. It was like I lost my identity because I was always the girl with pretty hair growing up.”

In order to diagnose someone with alopecia areata, a dermatologist will examine the area where the hair loss has occurred as well as a person’s nails, according to Dr. Johnson. Blood tests may be necessary to rule out other diseases caused by the immune system.

In addition to JAK inhibitors, treatment options for alopecia areata include contact immunotherapy, which can change your immune system so that it stops attacking your hair follicles; a disease-modifying antirheumatic medication called methotrexate; and corticosteroids, which are an anti-inflammatory medicine.

In Marten’s case, she was prescribed a JAK inhibitor.

Throughout her treatment, Martens said she tried to maintain a positive outlook and hope for the best. She said she feels blessed that the treatment worked for her.

“We now have more treatment options than ever before for alopecia areata patients, and they are providing results for people for whom previous treatments were not effective,” said Dr. Johnson. “It’s important to know that no one treatment works for everyone. Your board-certified dermatologist can recommend the treatment options that work best for you.”

# # #

Contact

Rhys Saunders, rsaunders@aad.org

Media Relations, mediarelations@aad.org

More Information

Alopecia Areata

About the AAD

Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram.

Editor’s note: The AAD does not promote or endorse any products or services. This content is intended as editorial content and should not be embedded with any paid, sponsored or advertorial content as it could be perceived as an AAD endorsement.